Skip to main content

As the situation in Ukraine evolves, businesses should be mindful of potential risks to their people, assets, operations, or supply chains in the region and globally. Marsh, as part of the Marsh McLennan family of companies, has created a page with information, tools, and resources related to the Russia-Ukraine conflict. Please visit the page for the latest information.

June 7, 2023

Dr. Monte Masten quoted in Leader’s Edge

While genetic testing is an effective way to identify and treat disease, it comes with a high cost for employers considering adding coverage for the technology to their insurance offerings.  

Dr. Monte Masten, Marsh McLennan Agency's Chief Medical Officer, spoke recently with Leader’s Edge about the most important components brokers and agents need to know about genetic testing and treatment coverage insurance plan offerings.

Monte says Marsh McLennan Agency counsels its brokers and clients on genetics-related issues. This includes whether to recommend that employer clients consider one or more of the increasing numbers of genomics-based services that are often pitched to them and brokers.

“I think, in a lot of situations, we typically recommend that they follow their insurer’s medical policies around genetic testing,” Monte says.

Read the full article in Leader's Edge here.